The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer
Open accessAbstract
Purpose: Hereditary factors play an important role in colorectal cancer (CRC) risk, yet the prevalence of germline cancer susceptibility gene mutations in patients with CRC unselected for high-risk features (eg, early age at diagnosis, personal/family history of cancer or polyps, tumor microsatellite instability [MSI], mismatch repair [MMR] deficiency) is unknown. Patients and Methods: We recruited 1,058 participants who received CRC care in a clinic-based setting without preselection for age at diagnosis, personal/family history, or MSI/MMR results. All participants underwent germline testing for mutations in 25 genes associated with inherited cancer risk. Each gene was categorized as high penetrance or moderate penetrance on the basis of published estimates of the lifetime cancer risks conferred by pathogenic germline mutations in that gene. Results: One hundred five (9.9%; 95% CI, 8.2% to 11.9%) of 1,058 participants carried one or more pathogenic mutations, including 33 (3.1%) with Lynch syndrome (LS). Twenty-eight (96.6%) of 29 available LS CRCs demonstrated abnormal MSI/MMR results. Seventy-four (7.0%) of 1,058 participants carried non-LS gene mutations, including 23 (2.2%) with mutations in high-penetrance genes (five APC, three biallelic MUTYH, 11 BRCA1/2, two PALB2, one CDKN2A, and one TP53), 15 of whom lacked clinical histories suggestive of their underlying mutation. Thirty-eight (3.6%) participants had moderate-penetrance CRC risk gene mutations (19 monoallelic MUTYH, 17 APC*I1307K, two CHEK2). Neither proband age at CRC diagnosis, family history of CRC, nor personal history of other cancers significantly predicted the presence of pathogenic mutations in non-LS genes. Conclusion: Germline cancer susceptibility gene mutations are carried by 9.9% of patients with CRC. MSI/MMR testing reliably identifies LS probands, although 7.0% of patients with CRC carry non-LS mutations, including 1.0% with BRCA1/2 mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Bibbins-Domingo, K., Grossman, D. C., Curry, S. J., Davidson, K. W., Epling, J. W., García, F. A. R., Gillman, M. W., Harper, D. M., Kemper, A. R., et al. (2016) · JAMA · doi:10.1001/jama.2016.5989 · Cited by 2,509
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
Landon, M., Saam, J., Brown, K. L., Moyes, K., Evans, B., & Wenstrup, R. (2015) · Oncology · doi:10.1159/000430097 · Cited by 1,939
Self-citationOlaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,671
Syngal, S., Brand, R. E., Church, J. M., Giardiello, F. M., Hampel, H. L., & Burt, R. W. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.435 · Cited by 1,662
Self-citationScreening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer)
Hampel, H., Frankel, W. L., Martin, E., Arnold, M., Khanduja, K., Kuebler, P., Nakagawa, H., Sotamaa, K., Prior, T. W., Westman, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043146 · Cited by 1,408
Robson, M. E., Bradbury, A. R., Arun, B., Domchek, S. M., Ford, J. M., Hampel, H. L., Lipkin, S. M., Syngal, S., Wollins, D. S., & Lindor, N. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0996 · Cited by 934
Self-citationGene-Panel Sequencing and the Prediction of Breast-Cancer Risk
Easton, D. F., Pharoah, P. D. P., Antoniou, A. C., Tischkowitz, M., Tavtigian, S. V., Nathanson, K. L., Devilee, P., Meindl, A., Couch, F. J., Southey, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmsr1501341 · Cited by 920
Feasibility of Screening for Lynch Syndrome Among Patients With Colorectal Cancer
Hampel, H., Frankel, W. L., Martin, E., Arnold, M., Khanduja, K., Kuebler, P., Clendenning, M., Sotamaa, K., Prior, T., Westman, J. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5950 · Cited by 876
Breast-Cancer Risk in Families with Mutations in PALB2
Antoniou, A. C., Casadei, S., Heikkinen, T., Barrowdale, D., Pylkäs, K., Roberts, J., Lee, A., Subramanian, D., De Leeneer, K., Fostira, F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400382 · Cited by 851
Giardiello, F. M., Allen, J. I., Axilbund, J. E., Boland, C. R., Burke, C. A., Burt, R. W., Church, J. M., Dominitz, J. A., Johnson, D. A., Kaltenbach, T., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.04.001 · Cited by 558
Self-citationIdentification of Lynch Syndrome Among Patients With Colorectal Cancer
Moreira, L., Balaguer, F., Lindor, N., de la Chapelle, A., Hampel, H., Aaltonen, L. A., Hopper, J. L., Le Marchand, L., Gallinger, S., Newcomb, P. A., et al. (2012) · JAMA · doi:10.1001/jama.2012.13088 · Cited by 556
Tung, N., Lin, N. U., Kidd, J., Allen, B. A., Singh, N., Wenstrup, R. J., Hartman, A.-R., Winer, E. P., & Garber, J. E. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.0747 · Cited by 556
Self-citationGeographical Variation in the Penetrance of CDKN2A Mutations for Melanoma
Bishop, D. T. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.12.894 · Cited by 509
Malkin, D. (2011) · Genes & Cancer · doi:10.1177/1947601911413466 · Cited by 508
Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer
Ramus, S. J., Song, H., Dicks, E., Tyrer, J. P., Rosenthal, A. N., Intermaggio, M. P., Fraser, L., Gentry-Maharaj, A., Hayward, J., Philpott, S., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv214 · Cited by 437
Counselling framework for moderate-penetrance cancer-susceptibility mutations
Tung, N., Domchek, S. M., Stadler, Z., Nathanson, K. L., Couch, F., Garber, J. E., Offit, K., & Robson, M. E. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.90 · Cited by 314
Yurgelun, M. B., Allen, B., Kaldate, R. R., Bowles, K. R., Judkins, T., Kaushik, P., Roa, B. B., Wenstrup, R. J., Hartman, A.-R., & Syngal, S. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.006 · Cited by 260
Self-citationPrevalence and Phenotypes of APC and MUTYH Mutations in Patients With Multiple Colorectal Adenomas
Grover, S., Kastrinos, F., Steyerberg, E. W., Cook, E. F., Dewanwala, A., Burbidge, L. A., Wenstrup, R. J., & Syngal, S. (2012) · JAMA · doi:10.1001/jama.2012.8780 · Cited by 246
Self-citationGermline MutY Human Homologue Mutations and Colorectal Cancer: A Multisite Case-Control Study
Cleary, S. P., Cotterchio, M., Jenkins, M. A., Kim, H., Bristow, R., Green, R., Haile, R., Hopper, J. L., LeMarchand, L., Lindor, N., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.12.050 · Cited by 228
Clinical Implications of the Colorectal Cancer Risk Associated With MUTYH Mutation
Lubbe, S. J., Di Bernardo, M. C., Chandler, I. P., & Houlston, R. S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6853 · Cited by 224
Bertario, L., Russo, A., Sala, P., Varesco, L., Giarola, M., Mondini, P., Pierotti, M., Spinelli, P., & Radice, P. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.118 · Cited by 210
Wood, M. E., Kadlubek, P., Pham, T. H., Wollins, D. S., Lu, K. H., Weitzel, J. N., Neuss, M. N., & Hughes, K. S. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4661 · Cited by 166
Population Frequency of Germline BRCA1/2 Mutations
Maxwell, K. N., Domchek, S. M., Nathanson, K. L., & Robson, M. E. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.0554 · Cited by 164
Grover, S., Stoffel, E. M., Bussone, L., Tschoegl, E., & Syngal, S. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00352-0 · Cited by 142
Self-citationIncidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study
the Hereditary Breast Cancer Study Group, Phelan, C. M., Iqbal, J., Lynch, H. T., Lubiński, J., Gronwald, J., Møller, P., Ghadirian, P., Foulkes, W. D., Armel, S. R., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.741 · Cited by 139
Gallego, C. J., Shirts, B. H., Bennette, C. S., Guzauskas, G. F., Amendola, L. M., Horike-Pyne, M. J., Hisama, F. M., Pritchard, C. C., Grady, W. M., Burke, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.3665 · Cited by 126
Judkins, T., Leclair, B., Bowles, K., Gutin, N., Trost, J., McCulloch, J., Bhatnagar, S., Murray, A., Craft, J., Wardell, B., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1224-y · Cited by 118
Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations
Kadouri, L., Hubert, A., Rotenberg, Y., Hamburger, T., Sagi, M., Nechushtan, C., Abeliovich, D., & Peretz, T. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2006.048173 · Cited by 99
BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer.
Niell, B., Rennert, G., Bonner, J., Almog, R., Tomsho, L., & Gruber, S. (2004) · Journal of the National Cancer Institute · doi:10.1093/jnci/djh008 · Cited by 98
Population-Based Molecular Screening for Lynch Syndrome: Implications for Personalized Medicine
Ward, R. L., Hicks, S. C., & Hawkins, N. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.8454 · Cited by 89
Woods, M. O., Younghusband, H. B., Parfrey, P. S., Gallinger, S., McLaughlin, J. R., Dicks, E. L., Stuckless, S. N., Pollett, A. F., Bapat, B. V., Mrkonjic, M., et al. (2010) · Gut · doi:10.1136/gut.2010.208462 · Cited by 88
McClain, M. R., Palomaki, G. E., Nathanson, K. L., & Haddow, J. E. (2005) · Genetics in Medicine · doi:10.1097/01.gim.0000151155.36470.ff · Cited by 85
Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer
Kastrinos, F., Ojha, R. P., Leenen, C. H., Alvero, C. G., Mercado, R. C., Balmañà, J., Valenzuela, I., Balaguer, F., Green, R., Lindor, N. M., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv308 · Cited by 47
Self-citationReply to percentage of colorectal cancer diagnoses in adults aged younger than 50 years
Abdelsattar, Z. M., Wong, S. L., Regenbogen, S. E., & Hendren, S. K. (2016) · Cancer · doi:10.1002/cncr.29977 · Cited by 1
Cited by
Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review
Biller, L. H., & Schrag, D. (2021) · JAMA · doi:10.1001/jama.2021.0106 · Cited by 2,604
Self-citationPatel, S. G., Karlitz, J. J., Yen, T., Lieu, C. H., & Boland, C. R. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00426-x · Cited by 812
Epidemiology and Mechanisms of the Increasing Incidence of Colon and Rectal Cancers in Young Adults
Stoffel, E. M., & Murphy, C. C. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.07.055 · Cited by 637
Increasing Incidence of Early-Onset Colorectal Cancer
Sinicrope, F. A. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2200869 · Cited by 534
Colorectal Cancer Epidemiology: Recent Trends and Impact on Outcomes
Baidoun, F., Elshiwy, K., Elkeraie, Y., Merjaneh, Z., Khoudari, G., Sarmini, M. T., Gad, M., Al-Husseini, M., & Saad, A. (2021) · Current Drug Targets · doi:10.2174/1389450121999201117115717 · Cited by 523
Metadata
- Authors
- Yurgelun, M. B., Kulke, M. H., Fuchs, C. S., Allen, B. A., Uno, H., Hornick, J. L., Ukaegbu, C. I., Brais, L. K., McNamara, P. G., Mayer, R. J., Schrag, D., Meyerhardt, J. A., Ng, K., Kidd, J., Singh, N., Hartman, A.-R., Wenstrup, R. J., & Syngal, S.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-04-01
- Volume
- 35
- Issue
- 10
- Pages
- 1086-1095
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2583869923
- Cited by
- 524
- References
- 36
- FWCI
- 31.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.